ClinicalTrials.gg
TerminatedNCT03355066Updated Aug 9, 2024

A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors

A Phase 1 interventional study of SM08502 in Solid Tumor, Adult, sponsored by Biosplice Therapeutics, Inc.. Terminated at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by Biosplice Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
Study was terminated due business reasons by Sponsor.

From the registry’s dates

  • Primary completion was Nov 2022, 4 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is an open-label, multi-center, dose-escalation, dose-finding and expansion study in adult subjects with advanced solid tumors for whom no standard therapy is available. The study will evaluate the safety, tolerability, PK, PD, and preliminary anti-tumor efficacy of SM08502 administered orally, once daily, following a 28-day treatment cycle (Part 1A). Alternative dosing schedules will be explored in Part 1B and the recommended Part 2 dose and schedule will be further evaluated in Part 2.

Subjects will participate in a screening period of up to 14 days. Dosing in 28-day cycles will continue within each subject, unless treatment is discontinued due to toxicity, disease progression, initiation of a new anti-neoplastic therapy, withdrawal of consent, the Sponsor terminates the study, or the subject no longer meets retreatment criteria.

Approximately 10 subjects enrolled in Part 2, irrespective of the tumor type, will be included in a food effect substudy to assess the preliminary effect of a high-fat, high-calorie meal on the PK of SM08502. Subjects participating in the food effect substudy will continue on study and complete assessments as per the Part 2 schedule and receive SM08502 at the recommended Part 2 dose (or another previously assessed dose level and schedule).

02

Conditions studied

  • Solid Tumor, Adult

Keywords

  • SM08502
  • pan Clk/Dyrk inhibitor
  • HRR
  • HRD
  • LOH High
  • AR-V7
03

In context

Lead sponsor

Biosplice Therapeutics, Inc. is the lead sponsor of 22 studies on the registry; none are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 12 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Subjects with advanced solid tumors (as defined below):

    1. Part 1A - Subjects with advanced solid tumors who are to or intolerant of established therapy known to provide clinical benefit for their condition (i.e., subjects must not be candidates for regimens known to provide clinical benefit) and for which histologic or cytologic confirmation of was obtained at diagnosis, with the exception of hepatocellular carcinoma if it meets appropriate imaging-only diagnostic criteria (per the National Comprehensive Cancer Network [NCCN], Liver Imaging Reporting and Data System [LI-RADS], American Association for the Study of Liver Diseases [AASLD], Asian Pacific Association for the Study of the Liver [APASL], or European Association for the Study of the Liver - European Organisation for Research and Treatment of Cancer [EASL-EORTC]).
    2. Part 1B - Subjects with advanced and/or solid tumors who are refractory to or intolerant of established therapy known to provide clinical benefit for their condition (i.e., subjects must not be candidates for regimens known to provide clinical benefit in the Investigator's judgment). Histologic or cytologic confirmation of malignancy must have been obtained at diagnosis. The tumor types include: i. NSCLC (adenocarcinoma subtype) ii. TNBC iii. CRPC iv. CRC v. Endometrial cancer (endometrioid subtype) vi. Ovarian cancer (serous, mucinous, and endometrioid subtypes).
    3. Part 2 - Subjects with advanced and/or metastatic solid tumors who are refractory to or intolerant of established therapy known to provide clinical benefit for their condition. Histologic or cytologic confirmation of malignancy must have been obtained at diagnosis. Subjects must have received no more than 2 prior lines of myelosuppressive chemotherapy. Additionally, CRPC subjects must have received no more than 4 total (including any hormonal therapies) in any setting. The tumor types include: i. NSCLC (adenocarcinoma subtype) ii. CRPC in two biomarker selected cohorts.
  2. Measurable or evaluable disease per 1.1 (Part 1A). For Parts 1B and 2, at least 1 per RECIST 1.1 that has not been previously irradiated. In CRPC subjects (Parts 1B and 2) without measurable disease per RECIST 1.1, a PSA that is concordant with clinical disease progression (rising) is eligible. A PSA value of 2 ng/ml or greater is required for study entry.
  3. Subjects must have archived tumor specimens available for analysis (as specified in Section 7.2.2). Otherwise, a fresh tumor will be required at study entry. At the discretion of the Sponsor's Medical Monitor, a fresh tumor biopsy may not be required for eligibility if there are extenuating circumstances (e.g., inaccessible sites of disease or lack of subject suitability to undergo a fresh biopsy, or molecular profiling of archived tissue already performed).
  4. Subjects must have recovered (i.e., Grade 1 [or better] based on v5.0) from all toxicity associated with previous chemotherapy, targeted therapy, experimental therapy, biological therapy, immuno-oncology therapy, surgery, radiotherapy, or other locoregional therapy (Exceptions include subjects with: continuing alopecia regardless of any CTCAE grade, Grade 2 or lower neuropathy, and well-controlled hypothyroidism and/or adrenal insufficiency on chronic hormone replacement. All subjects with these exceptions are eligible).
  5. (ECOG) performance status ≤ 1.

Key Exclusion Criteria:

  1. Women who are pregnant or lactating
  2. Women of (WOCBP) who do not agree to follow the guidelines as outlined in the study protocol
  3. Men of who do not agree to follow the contraceptive guidelines as outlined in the study protocol
  4. Subjects with a interval (QTc) using Fridericia's formula (QTcF) > CTCAE v5.0 Grade 1 (>480 msec) based on the mean of triplicate evaluation at Screening.
  5. Subjects with ventricular tachycardia (VT), atrial fibrillation (AF), ventricular fibrillation (VF), second or third degree heart block
  6. Subjects with myocardial infarction (MI) within 1 year, Class II-IV congestive heart failure (CHF) per (NYHA) classification, or clinically significant coronary artery disease (CAD)
  7. Subjects with active infection requiring parenteral antibiotic therapy.
  8. Organ transplant recipients.
  9. Subjects with known osteoporosis.
  10. Subjects with a second malignancy unless adequately treated with no recurrence for 3 years. Subjects with history of previous or recent adequately treated skin basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of any source are eligible.
  11. Subjects with active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of SM08502 per Investigator's opinion
  12. Subjects with known active (HIV), virus (HBV), or virus (HCV) infection
  13. Subjects with chronic liver disease or dysfunction and a score of B or C
  14. Subjects with untreated, progressing, or known symptomatic
  15. Subjects with retinal abnormalities, specifically diabetic retinopathy, macular degeneration, other forms of retinal degenerative disease, or other retinal findings that may place the subject at risk
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Part 1A: Dose Escalation

    Cohorts of subjects with advanced solid tumors will receive increasing doses (10, 20, 40, 60, 80, 120, 160, or 200 mg) of SM08502, administered orally, once daily, following 28-day treatment cycles. If the maximum tolerated dose (MTD) is not determined at the 200 mg dose, dosing will continue at 50 mg/dose increments until an MTD is determined. Cohorts will include approximately 1 to 6 subjects according to an accelerated escalation design and safety requirements for expansion of subject numbers. For the purpose of dose escalation and de-escalation, the dose of SM08502 and regimen may be modified based on the type of dose limiting toxicities (DLTs) observed and following data review and discussions between the Sponsor and Investigators.

    Drug: SM08502

  • Experimental
    Part 1B: Dose Finding

    Indications eligible for Part 1B include castration-resistant prostate cancer (CRPC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), endometrial cancer, or ovarian cancer for which histologic or cytologic confirmation of malignancy was obtained at diagnosis. Initially, two cohorts of 6-24 subjects will be evaluated comparing 2 different doses and schedules of SM08502 (30 mg daily and 40 mg 5 days on and 2 days off), administered orally following 28-day treatment cycles. If appropriate, alternative doses and schedules may be evaluated depending on the results.

    Drug: SM08502

  • Experimental
    Part 2: Expansion

    Part 2 will evaluate the recommended Part 2 dose and schedule of SM08502, as determined in Part 1B, in 3 cohorts of subjects. The indications to be evaluated include subjects with advanced and/or metastatic CRPC (two biomarker selection cohorts) and NSCLC for which histologic or cytologic confirmation of malignancy was obtained at diagnosis. Each cohort will enroll up to 20 subjects. Approximately 10 subjects of the total enrolled in Part 2, irrespective of cohort, will be included in a food-effect substudy to assess the preliminary effect of a high-fat, high-calorie meal on the PK of SM08502.

    Drug: SM08502

Interventions

  • SM08502 tablets to be administered orally.

06

What researchers measure

Primary outcomes

  1. Part 1A, Part 1B: Maximum tolerated dose (MTD) of SM08502 based on the frequency and severity of dose-limiting toxicities (DLTs)

    Time frame: DLT period of 28 days per dose level

  2. Part 1A, Part 1B and Part 2: Number of participants with treatment-emergent adverse events (TEAEs) as assessed by CTCAE v5.0

    Time frame: Approximately 5 years

  3. Part 1A, Part 1B and Part 2: Change from baseline in blood chemistry parameters: blood urea nitrogen [BUN], creatinine, glucose, potassium, sodium, calcium (micromoles per liter)

    Time frame: Approximately 5 years

  4. Part 1A, Part 1B and Part 2: Change from baseline in blood chemistry parameters: aspartate aminotransferase [AST], alanine aminotransferase (ALT), alkaline phosphatase [ALP] (international units per liter)

    Time frame: Approximately 5 years

  5. Part 1A, Part 1B and Part 2: Change from baseline in blood chemistry parameters: albumin (grams per day)

    Time frame: Approximately 5 years

  6. Part 1A, Part 1B and Part 2: Change from baseline in blood chemistry parameters: chloride, bicarbonate (millimoles per liter)

    Time frame: Approximately 5 years

  7. Part 1A, Part 1B and Part 2: Change from baseline in blood chemistry parameter: lactic acid dehydrogenase [LDH] (units per liter)

    Time frame: Approximately 5 years

  8. Part 1A, Part 1B and Part 2: Change from baseline in hematology parameter: hemoglobin [Hb] (grams per liter)

    Time frame: Approximately 5 years

  9. Part 1A, Part 1B and Part 2: Change from baseline in hematology parameter: hematocrit (proportion of red blood cells in blood)

    Time frame: Approximately 5 years

  10. Part 1A, Part 1B and Part 2: Change from baseline in hematology parameter: red blood cells [RBC] count (trillion cells per liter)

    Time frame: Approximately 5 years

  11. Part 1A, Part 1B and Part 2: Change from baseline in hematology parameters: neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelet count (cells/microliter)

    Time frame: Approximately 5 years

  12. Part 1A: Change from baseline in prothrombin time [PT] (seconds)

    Time frame: Approximately 5 years

  13. Part 1A: Change from baseline in partial thromboplastin time [PTT] (seconds)

    Time frame: Approximately 5 years

  14. Part 1A: Change from baseline in urinalysis parameter: clarity

    Time frame: Approximately 5 years

  15. Part 1A: Change from baseline in urinalysis parameter: specific gravity (ratio)

    Time frame: Approximately 5 years

  16. Part 1A: Change from baseline in urinalysis parameter: urine pH

    Time frame: Approximately 5 years

  17. Part 1A: Change from baseline in urinalysis parameter: protein

    Time frame: Approximately 5 years

  18. Part 1A: Change from baseline in urinalysis parameter: glucose (millimole per liter)

    Time frame: Approximately 5 years

  19. Part 1A: Change from baseline in urinalysis parameter: ketones (millimoles per liter)

    Time frame: Approximately 5 years

  20. Part 1A: Change from baseline in urinalysis parameter: occult blood (10^9 cells per liter)

    Time frame: Approximately 5 years

  21. Part 1A: Change from baseline in urinalysis parameter: nitrite

    Time frame: Approximately 5 years

  22. Part 1A: Change from baseline in urinalysis parameter: leukocytes (counts per high power field)

    Time frame: Approximately 5 years

  23. Part 1A, Part 1B and Part 2: Change from baseline in body temperature (degrees celsius)

    Time frame: Approximately 5 years

  24. Part 1A, Part 1B and Part 2: Change from baseline in pulse rate (beats per minute)

    Time frame: Approximately 5 years

  25. Part 1A, Part 1B and Part 2: Change from baseline in respiratory rate (breaths per minute)

    Time frame: Approximately 5 years

  26. Part 1A, Part 1B and Part 2: Change from baseline in blood pressure (systolic and diastolic) (millimeters of mercury)

    Time frame: Approximately 5 years

  27. Part 1A, Part 1B and Part 2: Change from baseline in electrocardiogram (ECG) parameters: PR interval, QRS interval, QT interval, QTcF (milliseconds)

    Time frame: Approximately 5 years

  28. Part 1A and Part 1B: Cmax of SM08502 and its metabolite (SM08955) following single dose administration of SM08502

    Time frame: Approximately 5 years

  29. Part 1A and Part 1B: tmax of SM08502 and SM08955 following single dose administration of SM08502

    Time frame: Approximately 5 years

  30. Part 1A and Part 1B: AUC0-24 of SM08502 and SM08955 following single dose administration of SM08502

    Time frame: Approximately 5 years

  31. Part 1A and Part 1B: AUClast of SM08502 and SM08955 following single dose administration of SM08502

    Time frame: Approximately 5 years

  32. Part 1A and Part 1B: Cmax,ss of SM08502 and SM08955 following repeat dose administration of SM08502

    Time frame: Approximately 5 years

  33. Part 1A and Part 1B: Cmin,ss of SM08502 and SM08955 following repeat dose administration of SM08502

    Time frame: Approximately 5 years

  34. Part 1A and Part 1B: tmax,ss of SM08502 and SM08955 following repeat dose administration of SM08502

    Time frame: Approximately 5 years

  35. Part 1A and Part 1B: AUC0-24,ss of SM08502 and SM08955 following repeat dose administration of SM08502

    Time frame: Approximately 5 years

  36. Part 2: Tumor response as measured by RECIST 1.1 (Response Evaluation Criteria In Solid Tumors) or PCWG3 (Prostate Cancer Working Group 3) criteria where appropriate

    Time frame: Approximately 5 years

Secondary outcomes

  1. Part 1A and Part 1B: Tumor response as measured by RECIST 1.1 or PCWG3 criteria where appropriate

    Time frame: Approximately 5 years

  2. Part 1A, Part 1B and Part 2: Gene expression profile of RNA isolated from whole blood

    Time frame: Approximately 5 years

  3. Part 2: Cmax of SM08502 and SM08955 following single dose administration of SM08502

    Time frame: Approximately 5 years

  4. Part 2: tmax of SM08502 and SM08955 following single dose administration of SM08502

    Time frame: Approximately 5 years

  5. Part 2: AUC0-24 of SM08502 and SM08955 following single dose administration of SM08502

    Time frame: Approximately 5 years

  6. Part 2: AUClast of SM08502 and SM08955 following single dose administration of SM08502

    Time frame: Approximately 5 years

  7. Part 2: Cmax,ss of SM08502 and SM08955 following repeat dose administration of SM08502

    Time frame: Approximately 5 years

  8. Part 2: Cmin,ss of SM08502 and SM08955 following repeat dose administration of SM08502

    Time frame: Approximately 5 years

  9. Part 2: tmax,ss of SM08502 and SM08955 following repeat dose administration of SM08502

    Time frame: Approximately 5 years

  10. Part 2: AUC0-24,ss of SM08502 and SM08955 following repeat dose administration of SM08502

    Time frame: Approximately 5 years

  11. Part 2: Gene expression and splicing alterations in post-treatment compared to pre-treatment tumor specimens

    Time frame: Approximately 5 years

  12. Part 2 Food Effect substudy: Cmax of SM08502 and SM08955 following single dose administration of SM08502 in fed and fasted states.

    Time frame: Approximately 5 years

  13. Part 2 Food effect substudy: tmax of SM08502 and SM08955 following single dose administration of SM08502 in fed and fasted states.

    Time frame: Approximately 5 years

  14. Part 2: AUC0-24 of SM08502 and SM08955 following single dose administration of SM08502 in fed and fasted states.

    Time frame: Approximately 5 years

07

Study locations

19 sites
  • Honor Health Research Institute
    Scottsdale, Arizona 85258, United States
  • University of Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • City of Hope Medical Center
    Duarte, California 91010, United States
  • UC Davis - Comprehensive Cancer Center
    Sacramento, California 95817, United States
  • Sarah Cannon Research Institute at HealthONE
    Denver, Colorado 80218, United States
  • Florida Cancer Specialists
    Sarasota, Florida 34232, United States
  • Northside Hospital
    Atlanta, Georgia 30342, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • START Midwest
    Grand Rapids, Michigan 49546, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Duke Cancer Institute
    Durham, North Carolina 27710, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • University of Oklahoma Medicine Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Vanderbilt University
    Nashville, Tennessee 37232, United States
  • NEXT Oncology
    San Antonio, Texas 78229, United States
  • UT Health San Antonio - Mays Cancer Center
    San Antonio, Texas 78229, United States
  • START Mountain Region
    West Valley City, Utah 84119, United States
08

References and documents

Publications

  • Moroney MR, Woodruff E, Qamar L, Bradford AP, Wolsky R, Bitler BG, Corr BR. Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer. Mol Carcinog. 2021 Aug;60(8):511-523. doi: 10.1002/mc.23308. Epub 2021 May 26. PubMed 34038589 ↗
  • Tam BY, Chiu K, Chung H, Bossard C, Nguyen JD, Creger E, Eastman BW, Mak CC, Ibanez M, Ghias A, Cahiwat J, Do L, Cho S, Nguyen J, Deshmukh V, Stewart J, Chen CW, Barroga C, Dellamary L, Kc SK, Phalen TJ, Hood J, Cha S, Yazici Y. The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models. Cancer Lett. 2020 Mar 31;473:186-197. doi: 10.1016/j.canlet.2019.09.009. Epub 2019 Sep 24. PubMed 31560935 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Nov 2022, 60 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2017
First posted
Nov 28, 2017
StartActual
Nov 6, 2017
Primary completionActual
Nov 14, 2022
CompletionActual
Nov 14, 2022
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03355066
Responsible party
Sponsor
First posted
Nov 28, 2017
Start date
Nov 6, 2017
Primary completion
Nov 14, 2022
Completion
Nov 14, 2022
Last update
Aug 9, 2024

Study contacts

Darrin Beaupre, MD, PhD, CMO
study chair · Biosplice Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SM08502

Start the discussion